BackTable Tumor Board
BackTable Tumor Board
Podcast Description
BackTable Tumor Board is a multi-disciplinary podcast for healthcare professionals that play an active role in cancer care. Season One features in-depth conversations on the topic of Hepatocellular Carcinoma (HCC) provided by a group of medical oncologists, interventional radiologists, hepatobiliary surgeons, hepatologists, and patient coordinators. Stay tuned for the next season!
Podcast Insights
Content Themes
The podcast explores various aspects of hepatocellular carcinoma, including treatment options, complex case discussions from tumor board meetings, and insights on the role of surgery, interventional oncology, and transplantation. Episodes feature detailed case reviews, such as the principles of practice in HCC tumor boards and tips for starting a career in interventional oncology.

BackTable Tumor Board is a multi-disciplinary podcast for healthcare professionals that play an active role in cancer care.
“If I have a complete pathological response, why do I need to get surgery?” It is one of the hottest questions in early-stage non-small cell lung cancer (NSCLC), and Dr. John Lazar hears it from his patients after neoadjuvant therapy. On this episode of the BackTable Lung Cancer Creator Weekend™, medical oncologist Dr. Kate Baker talks with Dr. Lazar, thoracic surgeon at Ascension Saint Thomas, about who should get neoadjuvant or perioperative therapy and how tumor size, nodal disease, histology, and molecular profiling shape the plan. They also discuss what a complete pathologic response does and does not tell a patient, why waiting more than six weeks from diagnosis to treatment raises the risk of upstaging, and how surgery changes after treatment has distorted the anatomy.
—
Get the BackTable app
https://www.backtable.com/app
—
This podcast is supported by
AstraZeneca
https://www.astrazeneca.com/
—
Timestamps
00:00 – Introduction
01:11 – Is Neoadjuvant or Perioperative Therapy the Standard?
02:32 – Tumor Features, Molecular Profiling, and Why Treat First
05:54 – Counseling on Pathologic Response
08:26 – Surgery After Neoadjuvant Therapy
09:42 – Getting Patients to Surgery: Toxicity and the Third Dose
12:07 – Complete Response, Adjuvant Immunotherapy, and Whether Less Is More
16:31 – Histology, Grade, and Biopsy Tissue
21:42 – Complete Response, PD-L1, and EGFR and ALK Results
24:36 – Counseling Patients and Smoking Cessation
27:11 – Lobectomy, Segmentectomy, or Wedge Resection
30:50 – Pitfalls: Communication and Time to Treatment
34:22 – Closing Remarks
—
More about this episode
Dr. Kate Baker and Dr. John Lazar trade questions across the surgeon and medical oncologist divide on circulating tumor DNA, whether fewer neoadjuvant cycles could be enough, PD-L1 status, and the EGFR and ALK results that change neoadjuvant strategy. Dr. Lazar shares how he counsels patients before treatment, why none of his patients go to the operating room smoking, how he chooses between lobectomy, segmentectomy, and wedge resection, and why poor communication between teams is the most preventable pitfall on the way to a goal of 28 days from diagnosis to treatment.
—
Resources
He J, et al. Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer (NeoADAURA). J Clin Oncol. 2025
https://doi.org/10.1200/JCO-25-00883
Forde PM, et al. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer (CheckMate 816). N Engl J Med. 2025
https://doi.org/10.1056/NEJMoa2502931
—
BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care.
Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.
► https://www.backtable.com/app

Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.